Category: Regulations
-
A.I. Mammogram Screening Shown to Improve Cancer Detection
Results of a clinical trial show one radiologist using software with artificial intelligence can detect more breast cancer cases in mammograms than current reviews by two radiologists.
-
Infographic – Nuclear Power Support Grows in U.S.
As the climate crisis focuses more attention on alternatives to fossil fuels, nuclear energy is gaining more popular support in the U.S. as one of those alternatives.
-
FDA Issues Guidance for Opioid Therapy Device Trials
The U.S. Food and Drug Administration issued new regulatory guidance for clinical trials of medical devices designed to prevent or treat opioid use disorder.
-
Trial Cleared for Lab-Grown Replacement Knee Cartilage
A biotechnology company creating living tissue from a person’s stem cells says it received FDA clearance for a clinical trial of its replacement knee cartilage.
-
Infographic – Most in U.S. Favor False Online Info Limits
A recent survey shows majorities of American adults would like technology companies or the government to restrict the spread of false information online.
-
One-Time Crispr HIV Therapy Given Fast-Track Status
A treatment for HIV taken just once, using the genome-editing technology Crispr, is receiving fast-track designation from the U.S. Food and Drug Administration.
-
Infographic – U.S. Public Backs A.I. Regulation
A recent survey shows a solid bipartisan majority of U.S. adults favors at least some government regulation of artificial intelligence, including people who say they use A.I.
-
Insurance Barriers, Migraine Hospital Visits Linked
A review of insurance claims shows patients facing obstacles to coverage for their migraine therapies are also more likely to need emergency care for treatment.
-
Real World Evidence Shown to Emulate Some Clinical Trials
A study of insurance claims records matching the design of randomized clinical trials shows claims data can in some cases resemble clinical trial results to make causal inferences.
-
Biotech Group Blasts Reproductive Drug Ruling
A biotechnology industry group calls Friday’s ruling in a Federal district court to suspend approval of the drug mifepristone “an assault on science.”